Brought to you by 
Abbott to develop companion Dx for Pfizer's NSCLC candidate
17 Aug 2011
Executive Summary
Abbott Molecular seeks to develop a diagnostic that can screen for non-small cell lung cancer (NSCLC) and identify patients who are eligible to receive Pfizer's PF2341066 oral cancer therapeutic.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com